Preventing Zika Virus (ZIKV) infection by vaccinating women may decrease risk of congenital Zika syndrome. Clinical trials are underway for inactivated, live attenuated, and DNA ZIKV vaccines. We sought to describe pregnant women’s attitudes toward participation in ZIKV vaccine research involving different vaccine platforms and to identify participation predictors and barriers.METHODS:
Women attending prenatal care in June and July 2017 were offered enrollment in an anonymous survey which asked women their views about participating in hypothetical ZIKV vaccine research scenarios during pregnancy. Demographics and Zika exposure during pregnancy were obtained.RESULTS:
Of 129 women, 70% expressed concern about ZIKV infection during pregnancy and 44% changed travel plans. Given the study scenarios, 68% stated they would consider an inactivated vaccine trial compared to 19% willing to participate in a live attenuated vaccine trial (p-value <0.0001). DNA vaccine trial acceptance was 51.6%. 57% of women believed the inactivated vaccine during pregnancy was safe for their baby compared to 26% for a live attenuated (p-value 0.012). Willing trial participants were most motivated by a desire to protect their babies from ZIKV, fewer were strongly motivated by a desire to contribute to science.CONCLUSION:
Inclusion of pregnant women in ZIKV vaccine trials is imperative to ensure vaccines are safe, effective, and acceptable in pregnancy. A majority of women in our cohort would accept participation in inactivated and DNA vaccine trials during pregnancy while fewer would participate in a trial of a live attenuated vaccine. Understanding women’s motivations for trial participation is critical to vaccine trial design.